RadNet’s Digital Health division, DeepHealth, introduced the DeepHealth Breast Suite on December 1 2025. The modular, AI‑powered suite is designed to enhance breast cancer detection, risk assessment, and clinical workflow for more than 10 million mammograms processed each year.
The suite bundles DeepHealth’s existing AI technologies—SaigeQ, SaigeDX, and Saige‑Density—alongside new modules for risk stratification and arterial calcification. Risk assessment is currently available in Europe, while the arterial calcification module is in development with a regulatory submission planned before the end of 2025.
Delivered on a cloud‑first platform, the Breast Suite integrates seamlessly with existing imaging workflows, providing real‑time AI insights that can be accessed from any imaging workstation or cloud portal.
The launch expands RadNet’s Digital Health revenue stream, which grew 51.6% to $24.8 million in Q3 2025 from $16.4 million in Q3 2024. The suite is expected to generate new high‑margin revenue from external sales, reinforcing the company’s upward guidance revision for 2025.
Strategically, the Breast Suite supports RadNet’s shift from reactive detection to proactive prevention. By offering a comprehensive AI solution that improves detection rates—studies show a 21.6% increase in cancer detection, especially for dense breasts and Black women—the company positions itself to capture additional market share in the high‑growth AI imaging market.
Analysts view the launch as a strengthening of RadNet’s competitive position, noting the suite’s robust clinical validation and the company’s continued focus on AI and cloud‑native technologies as key drivers of future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.